257 related articles for article (PubMed ID: 36620573)
1. Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review.
Ran R; Ma Y; Wang H; Yang J; Yang J
Front Oncol; 2022; 12():975463. PubMed ID: 36620573
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the treatment of hormone receptor-positive/human epidermal growth factor 2-positive advanced breast cancer.
Lv H; Yan M; Jiang Z
Ther Adv Med Oncol; 2021; 13():17588359211013326. PubMed ID: 33995599
[TBL] [Abstract][Full Text] [Related]
3. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
4. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.
Zhu L; Wang M; Luo X; Li H; Shan H; Du Q; Zhai Q
Ann Transl Med; 2022 Feb; 10(4):233. PubMed ID: 35280368
[TBL] [Abstract][Full Text] [Related]
5. Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2- breast cancer.
Patterson-Lomba O; Dalal AA; Ayyagari R; Liu O; Dervishi E; Platt E; Chandiwana D; O'Shaughnessy JA
Breast J; 2019 Sep; 25(5):880-888. PubMed ID: 31290203
[TBL] [Abstract][Full Text] [Related]
6. Endocrine therapy plus HER2-targeted therapy, another favorable option for HR+/HER2+ advanced breast cancer patients.
Liang Y; Liu X; Yun Z; Li K; Li H
Ther Adv Med Oncol; 2024; 16():17588359231220501. PubMed ID: 38188468
[TBL] [Abstract][Full Text] [Related]
7. Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer - Proceedings from breast cancer expert group meeting.
Dawood S; Konstantionva M; Dent R; Perazzo F; Kim SB; Villarreal-Garza C; Franco S; Dai MS; Simon S
BMC Proc; 2021 Aug; 15(Suppl 10):15. PubMed ID: 34372853
[TBL] [Abstract][Full Text] [Related]
8. Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer:: A Network Meta-analysis.
Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
Clin Ther; 2018 Apr; 40(4):628-639.e3. PubMed ID: 29609880
[TBL] [Abstract][Full Text] [Related]
9. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis.
Kawalec P; Łopuch S; Mikrut A
Clin Breast Cancer; 2015 Apr; 15(2):90-100.e1. PubMed ID: 25441421
[TBL] [Abstract][Full Text] [Related]
11. Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review.
Nagaraj G; Ma CX
Adv Ther; 2021 Jan; 38(1):109-136. PubMed ID: 33190190
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature.
Thanopoulou E; Khader L; Caira M; Wardley A; Ettl J; Miglietta F; Neven P; Guarneri V
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33182657
[TBL] [Abstract][Full Text] [Related]
13. Prospective Cohort Study of Combination Therapy With Abemaciclib and Hormonal Therapy for Chemotherapy-Treated Patients With Hormone Receptor-Positive Metastatic Breast Cancer.
Miyahara K; Narui K; Uemura Y; Yamada A; Araki K; Fujisawa F; Nakayama T; Ishikawa T; Taira N; Kikawa Y; Aihara T; Mukai H
World J Oncol; 2022 Aug; 13(4):216-221. PubMed ID: 36128594
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
Moy B; Rumble RB; Come SE; Davidson NE; Di Leo A; Gralow JR; Hortobagyi GN; Yee D; Smith IE; Chavez-MacGregor M; Nanda R; McArthur HL; Spring L; Reeder-Hayes KE; Ruddy KJ; Unger PS; Vinayak S; Irvin WJ; Armaghani A; Danso MA; Dickson N; Turner SS; Perkins CL; Carey LA
J Clin Oncol; 2021 Dec; 39(35):3938-3958. PubMed ID: 34324366
[TBL] [Abstract][Full Text] [Related]
15. Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US.
Li N; Hao Y; Kageleiry A; Peeples M; Fang A; Koo V; Wu EQ; Guérin A
Curr Med Res Opin; 2016; 32(2):385-94. PubMed ID: 26651842
[TBL] [Abstract][Full Text] [Related]
16. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.
Montemurro F; Di Cosimo S; Arpino G
Ann Oncol; 2013 Nov; 24(11):2715-24. PubMed ID: 23908178
[TBL] [Abstract][Full Text] [Related]
17. Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer.
Pegram M; Pietras R; Dang CT; Murthy R; Bachelot T; Janni W; Sharma P; Hamilton E; Saura C
Ther Adv Med Oncol; 2023; 15():17588359231187201. PubMed ID: 37576607
[TBL] [Abstract][Full Text] [Related]
18. Tumor hormone/HER2 receptor status and pharmacologic treatment of metastatic breast cancer in Western Europe.
Gao S; Barber B; Schabert V; Ferrufino C
Curr Med Res Opin; 2012 Jul; 28(7):1111-8. PubMed ID: 22587480
[TBL] [Abstract][Full Text] [Related]
19. Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice.
Brufsky A; Liu X; Li B; McRoy L; Layman RM
Target Oncol; 2021 Sep; 16(5):601-611. PubMed ID: 34338965
[TBL] [Abstract][Full Text] [Related]
20. A shift in the treatment of hormone receptor and human epidermal growth factor receptor 2-positive metastatic breast cancer.
Kemp Z; Jones A
Adv Ther; 2011 Aug; 28(8):603-14. PubMed ID: 21833702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
